HOME >> BIOLOGY >> NEWS
Resveratrol synthase uncovered: Cyclization specificity of type III polyketide synthases

A group from the Salk institute illuminates the structural basis for tetraketide cyclization in stilbene synthase, the enzyme that produces resveratrol, the beneficial phytonutrient found in red wine.

Plant natural products called stilbenes can confer antifungal resistance to host plants and have been shown to possess health benefits for humans and other animals when present in their diet. The best known stilbene is resveratrol, which is found in grapes and is believed to be a major contributor to the "French Paradox," which refers to the health benefits associated with the moderate consumption of red wine. The mechanism of stilbene synthesis is therefore of great pharmaceutical and medical interest. Much is already understood about the enzymatic features of type III polyketide synthases, the enzyme family that generates stilbenes, but until now one mystery remained: How are stilbene synthases regulated to conduct the specific cyclization reaction required to produce stilbenes? For example, stilbene synthase (STS) and chalcone synthase (CHS) share 75%90% amino acid sequence identity and generate the same tetraketide, but STS enzymes cyclize this tetraketide via an intramolecular C2 to C7 aldol condensation to make stilbene, whereas the CHS cyclize via C2 to C6 condensation reaction to make chalcone. A group of researchers led by Joseph Noel at the Salk Institute has revealed the structural basis for the specificity of this critical reaction. To do this, the Noel group generated the first crystal structure of a STS and identified how STS evolved from its CHS ancestor by comparing the two at the structural and molecular levels. To prove their hypothesis, the Noel group used this information to convert alfalfa CHS into a functional STS by structure-guided engineering. Their work reveals an unexpected mechanism for functional divergence of the STS from the CHS. Specificity of cyclization is not regulated by the shape of the active site, as was believed prev
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
17-Sep-2004


Page: 1 2

Related biology news :

1. Genes can influence both alcohol consumption and dependence
2. Genes may be central to cocaine addiction
3. Genes appear to play a role in development of chronic obstructive pulmonary disease
4. Genes make the marsh
5. Genes predict response of adult leukemia patients to chemotherapy
6. Genes influence memory in families with Alzheimers disease
7. Genes control severity of heart failure, study finds
8. Genes that regulate hearing link humans and fruit flies in new way
9. Genes discovered that regulate blood stem cell development
10. Genes that paint fly derrieres hint at convergence
11. Genes, Brain and Behavior Symposium April 16

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: